Palosuran hydrochloride

CAS No. ——

Palosuran hydrochloride ( —— )

Catalog No. M17710 CAS No. ——

Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 188 Get Quote
10MG 292 Get Quote
25MG 474 Get Quote
50MG 677 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Palosuran hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
  • Description
    Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    Urotensin Receptor (GPR14)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    454.99
  • Molecular Formula
    C25H31ClN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.Cc2nc1ccccc1c(c2)NC(=O)NCCN3CCC(O)(CC3)Cc4ccccc4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Clozel M, et al. J Pharmacol Exp Ther, 2004, 311(1):204-212.
molnova catalog
related products
  • PI3Kα-IN-4h

    PI3Kα-IN-1 is a potent, selective, ATP-competitive dual PI3Kα/mTOR inhibitor with IC50 of 0.5/104 nM respectively.

  • AZD8186

    AZD8186 is a potent, isoform-specific PI3Kβ inhibitor with IC50 of 4 nM, also inhibits PI3Kδ (IC50=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).

  • Dactolisib

    A potent, dual ATP-competitive pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM, respectively.